Pembina Pipeline Corporation is maintained as a Buy with a 10-17% upside and a base price target of $55.65 ahead of its Q3 earnings release on November 5. The company benefits from high energy prices and AI-driven gas demand supporting its contracted cash flows, despite pressures from inflation and interest rates on costs and future demand. Analysts expect Q3 EPS of $0.48, a 45% increase year-over-year, though revenue growth may overstate earnings due to low marketing margins. Capital expenditures and operating cash flow face challenges this year, but the dividend outlook remains supported by projected cash recovery and resilient EBITDA.
Pembina Pipeline is the subject of this report, with Pluang's Energy sector data providing market context as of Nov 04, 2026 04:21 WIB. Among 79 priced Energy-sector US stocks tradable on Pluang, 27 rose and 51 fell today. Notable movers include SM Energy Company Common Stock at USD 34.32 with a 1-day change of -8.33% and Pluang order activity showing 100% Sell, Solaredge Technologies Inc at USD 32.52 up 7.66% with 100% Sell orders, and Equinor ASA at USD 45.42 down 6.83% but with 100% Buy orders. The most notable figure is SM Energy's 100% Sell order activity.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
